Recent hot topics in contrast media

European Radiology

Volumn 21, Issue 3, 2011, Pages 492-495

  Thomsen, Henrik S ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adverse reactions; Contrast induced nephropathy; Contrast media; Gadolinium based contrast media; Iodine based contrast media; Nephrogenic systemic fibrosis

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; GADOLINIUM; IODINATED CONTRAST MEDIUM; IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL;

COMPUTER ASSISTED TOMOGRAPHY; CONTRAST INDUCED NEPHROPATHY; DRUG EFFECT; DRUG SAFETY; HUMAN; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OFF LABEL DRUG USE; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION;

CONTRAST MEDIA; DRUG TOXICITY; GADOLINIUM; HUMANS; IODINE; MAGNETIC RESONANCE IMAGING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79751524714     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-010-2026-x     Document Type: Review

References (31)

1. HS Thomsen JW Archer L Schiermer PW Radensky 1998 The financial impact of Denmark's decision to restrict the use of high-osmolar contrast media in intravascular radiographic procedures Eur Radiol 8 321 322 1:STN:280: DyaK1c7ktl2jsQ%3D%3D 10.1007/s003300050389 9477291
2. M Tepel M van der Giet C Schwartzfeld, et al. 2000 Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine N Engl J Med 343 180 184 1:CAS:528:DC%2BD3cXlsF2jsrs%3D 10.1056/NEJM200007203430304 10900277 (Pubitemid 30489215)
3. HS Thomsen 2001 Contrast-medium-induced nephrotoxicity: are all answers in for Acetylcysteine? Eur Radiol 11 2351 2353 1:STN:280:DC%2BD3MnovVajtA%3D%3D 10.1007/s003300101054 11734930 (Pubitemid 33114889)
4. JH Ellis RH Cohan 2009 Reducing the risk of contrast induced nephropathy. A perspective on the controversies AJR Am J Roentgenol 192 1544 1549 10.2214/AJR.09.2368 19457817
5. P Aspelin P Aubry SG Fransson, et al. 2003 Nephrotoxic effects in high-risk patients undergoing angiography N Engl J Med 348 491 499 1:CAS:528:DC%2BD3sXovVKmsA%3D%3D 10.1056/NEJMoa021833 12571256 (Pubitemid 36159884)
6. W Laskey P Aspelin C Davidson, et al. 2009 Nephrotoxicity of iodixanol versus iopamidol in patients with chroinic disease and diabetes undergoing coronary angiographic procedures Am Heart J 158 822 828 1:CAS:528: DC%2BD1MXhtlSqsrjE 10.1016/j.ahj.2009.08.016 19853704
7. Thomsen HS, Morcos SK (2006) Contrast-medium-induced nephropathy: is there a new consensus? A review of published guidelines. Eur Radiol 16:1835-1840 (Pubitemid 44027388)
8. MC Heinrich L Häberle V Müller, et al. 2009 Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials Radiology 250 68 86 10.1148/radiol.2501080833 19092091
9. M Reed P Meier UU Tamhane, et al. 2009 The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials JACC Cardiovasc Interv 2 645 654 10.1016/j.jcin.2009.05.002 19628188
10. HS Thomsen SK Morcos 2008 Risk of contrast medium-induced nephropathy in high-risk patients undergoing MDCT - a pooled analysis of two randomized trials Eur Radiol 18 891 897
11. H Hoppe S Spagnuolo JM Froehlich, et al. 2010 Retrospective analysis of patients for development of nephrogenic systemic fibrosis following conventional angiography using gadolinium-based contrast agents Eur Radiol 20 595 603 10.1007/s00330-009-1586-0 19760239
12. HS Thomsen T Almén SK Morcos, et al. 2002 Gadolinium-containing contrast media for radiographic examination: a position paper Eur Radiol 12 2600 2605 12271402 (Pubitemid 36940367)
13. HS Thomsen 2004 Gadolinium-based contrast media may be nephrotoxic even at approved doses (case report) Eur Radiol 14 1654 1656 15221265 (Pubitemid 39232897)
14. B Elmståhl U Nyman P Leander, et al. 2006 Gadolinium contrast media are more nephrotoxic than iodine media. The importance of osmolality in direct renal artery injections Eur Radiol 16 2712 2720 10.1007/s00330-006-0357-4 16896701 (Pubitemid 44823924)
15. P Reimer R Vosshenrich 2008 Off-label use of contrast agents Eur Radiol 18 1096 1101 1:STN:280:DC%2BD1cvhsV2ktQ%3D%3D 10.1007/s00330-008-0886-0 18274752
16. HS Thomsen 2006 Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide Eur Radiol 16 2619 2621 10.1007/s00330-006-0495-8 17061066 (Pubitemid 44823915)
17. T Leiner C Herborn M Goyen 2007 Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide Euro Radiol 17 1921 1923 10.1007/s00330-007-0663-5 (Pubitemid 47097447)
18. SK Morcos 2010 Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far? Eur Radiol 10.1007/s00330-010-1951-z 20848109
19. CH Evans BJ Drouven 1983 The promotion of collagen polymerization by lanthanide and calcium ions Biochem J 213 751 758 1:CAS:528:DyaL3sXltVWhs7Y%3D 6615457
20. BJ Brouven CK Evans 1986 Collagen fibrillogenesis in the presence of lathanides J Biol Chim 261 11792 11797
21. SMRM workshop on contrast enhanced magnetic resonance 1991 Discussion Magn Reson Med 22 229 232 10.1002/mrm.1910220213
22. GW White WA Gibby MF Tweedle 2006 Comparison of Gd (DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy Invest Radiol 41 272 8 10.1097/01.rli.0000186569.32408.95 16481910 (Pubitemid 44406188)
23. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB (1999) Gadolinium (III) chelates and MRI agents: Structure, dynamics and applications. Chem Rev 99:2293-2352
24. TJ Wadas CD Sherman JH Miner, et al. 2010 The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice Magn Reson Med 64 5 1274 80 10.1002/mrm.22553 1:CAS:528:DC%2BC3cXhsFamtrvO 10.1002/mrm.22553 20648683
25. COMMISSION DECISION of 1.7.2010 concerning, in the framework of Article 31 of Directive 2001/83/EC of the European Parliament and of the Council, the marketing authorisations for Gadolinium-containing contrast agents for human use which contain one or more of the active substances "gadodiamide, gadopentetic acid, gadobenic acid, gadoxetic acid, gadoteridol, gadobutrol and gadoteric acid". http://ec.europa.eu/health/documents/community-register/ html/refh-others.htm. Accessed November 1st 2010
26. I Böhm HH Schild 2006 A practical guide to diagnose lesser-known immediate and delayed contrast media-induced adverse cutaneous reactions Eur Radiol 16 1570 1579 10.1007/s00330-006-0202-9 16770655 (Pubitemid 43871830)
27. HS Thomsen SK Morcos 2004 Management of acute adverse reactions to contrast media Eur Radiol 14 476 481 10.1007/s00330-003-2214-z 14740165 (Pubitemid 38324923)
28. SK Morcos WJAW Thomsen 2001 Prevention of generalized reactions to contrast media: a consensus report and guidelines Eur Radiol 11 1720 1728 1:STN:280:DC%2BD3Mvms1CrtA%3D%3D 10.1007/s003300000778 11511894 (Pubitemid 32821379)
29. CB Lightfoot RJ Abraham T Mammen 2009 Survey of radiologist's knowledge regarding the management of severe contrast material-induced allergic reactions Radiology 251 691 696 10.1148/radiol.2513081651 19474374
30. H Munechika Y Hiramatsu S Kudo, et al. 2003 A prospective survey of delayed adverse reactions to iohexol in urography and computed tomography Eur Radiol 13 185 194 10.1007/s00330-003-2024-3 12541129 (Pubitemid 38008313)
31. JAW Webb F Stacul HS Thomsen SK Morcos 2003 Late reactions to intravascular iodinated contrast media Eur Radiol 13 181 184 10.1007/s00330-003-1874-z 12541128 (Pubitemid 38008312)